VBI Vaccines Inc. (NASDAQ:VBIV) Sees Large Drop in Short Interest

VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) was the recipient of a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 16,520,000 shares, a decline of 23.7% from the June 15th total of 21,660,000 shares. Approximately 6.8% of the shares of the stock are sold short. Based on an average daily volume of 2,470,000 shares, the short-interest ratio is presently 6.7 days.

Institutional Trading of VBI Vaccines

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. grew its stake in VBI Vaccines by 2.0% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 2,233,150 shares of the biopharmaceutical company’s stock worth $1,806,000 after acquiring an additional 43,450 shares during the period. Bank of America Corp DE grew its stake in shares of VBI Vaccines by 88.9% during the 1st quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 380,839 shares during the period. State Street Corp grew its stake in shares of VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company’s stock valued at $26,920,000 after buying an additional 3,844,698 shares during the period. Engineers Gate Manager LP purchased a new stake in shares of VBI Vaccines during the 1st quarter valued at $26,000. Finally, Invesco Ltd. grew its stake in shares of VBI Vaccines by 24.8% during the 1st quarter. Invesco Ltd. now owns 479,765 shares of the biopharmaceutical company’s stock valued at $797,000 after buying an additional 95,408 shares during the period. 43.24% of the stock is owned by hedge funds and other institutional investors.

VBI Vaccines Trading Down 2.3 %

Shares of VBI Vaccines stock opened at $0.79 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 3.31 and a quick ratio of 3.19. VBI Vaccines has a 1 year low of $0.64 and a 1 year high of $3.81. The company has a market capitalization of $205.19 million, a P/E ratio of -2.84 and a beta of 1.98. The business has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.34.

VBI Vaccines (NASDAQ:VBIV – Get Rating) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. VBI Vaccines had a negative return on equity of 48.77% and a negative net margin of 16,087.72%. Sell-side analysts anticipate that VBI Vaccines will post -0.27 EPS for the current fiscal year.

About VBI Vaccines

(Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Recommended Stories

• Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
• Should you buy Bank of America Stock After Its Q2 Earnings Report?
• Is it Time to Cash Out Novavax Stock?
• Monthly Dividend Stocks Can Provide Solid Income
• AMC Entertainment Is On Track For Blockbuster Results 
• Abbott Labs Stock Can Be a Recession Hedge for Your Portfolio

Want More Great Investing Ideas?